🔗 Share this article

Given that America continues making historic revisions to its vaccination guidelines, a particular individual has emerged unexpectedly: Høeg, a Danish American sports physician and epidemiologist who first made her name by questioning coronavirus vaccines in the global health crisis and has focused upon possible deaths following COVID-19 vaccination in her recent time at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Schedule

Public health authorities planned to announce sweeping revisions to the pediatric immunization program earlier this month, synchronizing the US with the Danish national calendar, sources say – a significant shift that would put the US out of alignment with many the global community with insufficient data for improved outcomes. The planned update has been delayed until the coming year.

In place of the top vaccines chief, Høeg is scheduled to present at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to lead the center this year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the drug and biologics branches as Høeg and Dr. Prasad consolidate power at the agency – and it suggests a greater focus upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for halting certain pediatric shot schedules in the US in order to be more like Denmark's approach, a nation with comprehensive healthcare and a citizenry roughly the size of the state of Wisconsin.

So far statements, she has continued to focus on immunizations – typically the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Doubts Over Expertise

Høeg has little discernible track record in drug development, oversight or leadership, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and CBER since March.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in leading a sizeable institution. She lacks background in industry regulation.”

Past directors of the center would “grasp regulatory frameworks and the underlying principles of drug development”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the sort of resume that previous people who led CBER have had.”

This division has an immense portfolio at the agency, the former commissioner stated.

“Everybody just focuses on the novel medication approvals, but the generic program authorizes a multitude of generic drugs. There’s a biosimilars division, OTC medication office and other areas, and every single one must be managed,” Woodcock said. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial leadership element to the role, which oversees in excess of 5,000 staff members. “It is a huge leadership role, if you do it right,” Woodcock said.

Response and Controversial Initiatives

When asked about concerns about Høeg’s qualifications and whether this selection indicates greater collaboration among FDA leaders on vaccines, a spokesperson stated that the “questions are based on inaccurate presumptions”.

“Her resume is consistent with the duties of her role,” the representative stated, pointing to the months Dr. Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a controversial expedited drug-approval program that allegedly worried her former heads. “By what process are these drugs being picked for this voucher program? Who takes the decisions?” Dr. Howard asked. “There’s a lot of confidentiality going on at the regulatory body right now.”

In general, he remarked, “the FDA appears to be shifting towards more relaxed rules of pharmaceuticals, aside from immunizations.”

Established History on Vaccines

Regarding vaccines, Høeg has a more established, if concerning, history, critics observe. She authored a analysis using unconfirmed volunteer-provided data to estimate the incidence of myocarditis after Covid immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to imply Covid vaccinations are riskier than they are.

Part of her “policy goals” for the new government included revising regulations for new vaccines and halting “unnecessary” immunizations, she stated following the vote on a online show. At the agency, Høeg has reportedly suggested barring teenage boys from receiving Covid vaccinations.

“She’s an thorough dogmatist who starts off with her beliefs and tailors the evidence to fit the science in a highly deceptive, untruthful way,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of other dissenters, {like|